首页> 外文OA文献 >Vesicle budding from endoplasmic reticulum is involved in calsequestrin routing to sarcoplasmic reticulum of skeletal muscles.
【2h】

Vesicle budding from endoplasmic reticulum is involved in calsequestrin routing to sarcoplasmic reticulum of skeletal muscles.

机译:从内质网发芽的囊泡参与钙网蛋白路由至骨骼肌的肌质网。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

CS (calsequestrin) is an acidic glycoprotein of the SR (sarcoplasmic reticulum) lumen and plays a crucial role in the storage of Ca2+ and in excitation-contraction coupling of skeletal muscles. CS is synthesized in the ER (endoplasmic reticulum) and is targeted to the TC (terminal cisternae) of SR via mechanisms still largely unknown, but probably involving vesicle transport through the Golgi complex. In the present study, two mutant forms of Sar1 and ARF1 (ADP-ribosylation factor 1) were used to disrupt cargo exit from ER-exit sites and intra-Golgi trafficking in skeletal-muscle fibres respectively. Co-expression of Sar1-H79G (His79-->Gly) and recombinant, epitope-tagged CS, CSHA1 (where HA1 stands for nine-amino-acid epitope of the viral haemagglutinin 1), barred segregation of CSHA1 to TC. On the other hand, expression of ARF1-N126I altered the subcellular localization of GM130, a cis -medial Golgi protein in skeletal-muscle fibres and myotubes, without interfering with CSHA1 targeting to either TC or developing SR. Thus active budding from ER-exit sites appears to be involved in CS targeting and routing, but these processes are insensitive to modification of intracellular vesicle trafficking and Golgi complex disruption caused by the mutant ARF1-N126I. It also appears that CS routing from ER to SR does not involve classical secretory pathways through ER-Golgi intermediate compartments, cis -medial Golgi and trans -Golgi network.
机译:CS(calsequestrin)是SR(肌浆网)内腔的酸性糖蛋白,在Ca2 +的储存和骨骼肌的兴奋收缩耦合中起着至关重要的作用。 CS是在ER(内质网)中合成的,并通过很大程度上未知的机制靶向SR的TC(末端池),但可能涉及通过高尔基复合体的囊泡转运。在本研究中,Sar1和ARF1(ADP-核糖基化因子1)的两种突变形式分别用于破坏从ER出口位点出来的货物出口和骨骼肌纤维中的高尔基体内运输。 Sar1-H79G(His79-> Gly)与重组,带有表位标签的CS,CSHA1(其中HA1代表病毒血凝素1的9个氨基酸表位)共同表达,禁止CSHA1与TC分离。另一方面,ARF1-N126I的表达改变了GM130的亚细胞定位,GM130是骨骼肌纤维和肌管中的一种顺式-中间高尔基体蛋白,而不会干扰CSHA1靶向TC或正在发育的SR。因此,来自ER出口位点的活跃出芽似乎参与了CS的靶向和路由,但是这些过程对突变型ARF1-N126I引起的细胞内囊泡运输的改变和高尔基复合体破坏不敏感。从ER到SR的CS路由也似乎不涉及通过ER-Golgi中间区室,顺式-高尔基体和反式-Golgi网络的经典分泌途径。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号